Skip to main content
. 2022 Feb 7;10(2):e003465. doi: 10.1136/jitc-2021-003465

Figure 1.

Figure 1

ITGB6 promotes tumor growth by inhibiting the T-cell antitumor immune response. (A) Western blot for ITGB6 in MC38 and CT26 cells that overexpress ITGB6. (B) 3-day proliferation assay with ITGB6 overexpressing and control cells. (C) CT26-ITGB6 and CT26-Ctrl cecum tumors at day 13 after injection into Balb/c mice. (D) Weight of CT26-ITGB6 and CT26-Ctrl cecum tumors at day 13 after injection. (E) Flow cytometry analysis of CD8+ T cells isolated from tumor. (F) Flow cytometry analysis of CD4+ T cells isolated from tumor. (G) Flow cytometry analysis of CD8+ and CD4+ T cells isolated from spleen and lymph node (LN). (H) CT26-ITGB6 and CT26-Ctrl cecum tumors at day 13 after injection into Balb/c nude mice. (I) Weight of CT26-ITGB6 and CT26-Ctrl cecum tumors at day 13 after injection into Balb/c nude mice. Means and SDs are shown (n=5 mice). Unpaired two-tailed t-test was used to calculate statistical significance. ns=not significant (p≥0.05), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.